← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Enzyme By Design, Inc.
Chicago, IL
$3,896,333
Total funding
6
Grants
Funding over time
peak $1.7M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,896,333 · 6
By mechanism
R44$1,993,539 · 1
R43$1,249,937 · 3
R41$652,857 · 2
Investigators at Enzyme By Design, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$1,156,734
R44 · FY2020 · CA
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$836,804
R44 · FY2022 · CA
Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy$400,000
R43 · FY2024 · CA
Extending the in vivo half-life of a novel engineered mammalian asparaginase via its binding to human serum albumin$399,999
R43 · FY2020 · CA
Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase$299,939
R43 · FY2019 · CA
Development of a novel safe and efficacious biologic drug for the treatment of AML$299,552
R41 · FY2018 · CA
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$298,305
R41 · FY2018 · CA
Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase$149,999
R43 · FY2020 · CA
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$55,000
R41 · FY2019 · CA
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$1
R44 · FY2021 · CA